Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

1.280 +0.020 (+1.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin
Via ACCESSWIRE
Researchers Discuss How Brain Cancer Radiotherapy Side Effects Can Be Reduced
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Interim Analysis on Global Berubicin Trial Showing Promising Results
Via Investor Brand Network
Topics Death
Exposures Death
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
Via ACCESSWIRE
CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference
Via ACCESSWIRE
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
Every form of cancer is devastating, but the unfortunate reality is not all cancers are created equal. There are certain forms that are more deadly, with Glioblastoma (GBM) being one of the worst. GBM... 
Via Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Updated Safety Data from Berubicin Study at SNO Annual Gathering
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
Via ACCESSWIRE
Study Finds DNA Loops in Brain Tumors in Kids Amplify Relapse Risk
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Release Interim Data by Year End for Lead Treatment Candidate Berubicin
Via Investor Brand Network
Topics Death
Exposures Death
CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2023 Financial Results, Update on Berubicin Study
Via Investor Brand Network
CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate
Glioblastoma is a highly aggressive type of brain cancer with no cure, leading to a grim prognosis and average survival time of only 14 to 16 months. With no approved treatment for recurrent GBM... 
Via Benzinga
CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End
Via ACCESSWIRE
Brain Cancer Reemergence Could Soon Be Detected Using a Finger-Prick Test
Via Investor Brand Network
Stanford Study Finds Lung Cancer Cells Hide, Thrive in the Brain
Via Investor Brand Network
Spanish Clinical Trial to Explore Marijuana as Glioblastoma Treatment
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Drive Toward Potential New GBM Treatment
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Announces Participation at Upcoming Virtual Investor Ask the CEO Conference
Via Investor Brand Network
Sonobiopsy Promises Easier Way to Diagnose Brain Tumors
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Innovative Glioblastoma Treatment ‘Could Offer Hope’
Via Investor Brand Network
Exposures Product Safety
Glioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure - CNS Pharmaceuticals’ Innovative Approach To Treatment Could Offer Hope
Via ACCESSWIRE
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday. 
Via Benzinga
Glioblastoma Is the Most Aggressive Type Of Brain Cancer, With No Cure – CNS Pharmaceuticals' Innovative Approach To Treatment Could Offer Hope
Glioblastoma is the most aggressive type of brain cancer, with an average survival of only 14 to 16 months after diagnosis. There is currently no cure for glioblastoma, and it is a highly invasive... 
Via Benzinga
Researchers Look for Novel Immunomodulating Targets with Potential to Transform Glioblastoma Treatment
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Rapid Pace of Enrollment in Potentially Pivotal Berubicin Study
Via Investor Brand Network
CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
Via ACCESSWIRE
First Time Ever: Researchers Eliminate Brain Cancer Using Quantum Therapy
Via Investor Brand Network
Novel Type of Immunotherapy Exhibits Efficacy Against Brain Tumors in Mouse Models
Via Investor Brand Network
Surgical Robot Prototype Could Ease Pediatric Brain Cancer Surgery
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.